193079-69-5

Basic information

• Product Name: Tabimorelin
• Synonyms: Tabimorelin;Tabimorelin [inn];Unii-L51cbe03kf;N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamidehemifumarate
• CAS NO: 193079-69-5
• Molecular Formula: C₃₂H₄₀N₄O₃
• Molecular Weight: 1173.46
• Product Categories: Amines;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 193079-69-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 794.4°Cat760mmHg
• Flash Point: 434.2°C
• Appearance: /
• Density: 1.146g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Desiccate at RT
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• Stability: Light Sensitive
• CAS DataBase Reference: Tabimorelin(CAS DataBase Reference)
• NIST Chemistry Reference: Tabimorelin(193079-69-5)
• EPA Substance Registry System: Tabimorelin(193079-69-5)

Safety Data

• Hazardous Substances Data: 193079-69-5(Hazardous Substances Data)

Usage

Description

Tabimorelin, also known as NN703, is an orally active growth hormone (GH) secretagogue. It is designed to serve as an alternative to daily injections of growth hormone, offering a more convenient and potentially less invasive method for hormone regulation. Tabimorelin has been shown to act as a mechanism-based inhibitor of CYP3A4 in in vitro studies conducted using human liver microsomes.

Uses

Used in Hormone Regulation:
Tabimorelin is used as a growth hormone secretagogue for the purpose of stimulating the natural production of growth hormone in the body. This application is particularly relevant for individuals who require growth hormone supplementation but may prefer a non-invasive, oral alternative to daily injections.
Used in Pharmaceutical Research:
In the context of pharmaceutical research, Tabimorelin is used as a tool to study the mechanisms of growth hormone secretion and its regulation. Its role as a mechanism-based inhibitor of CYP3A4 also makes it a valuable compound for investigating the interactions between growth hormone secretagogues and the cytochrome P450 enzyme system, which is involved in the metabolism of various drugs and substances in the body.
Used in Clinical Trials:
Tabimorelin is utilized in clinical trials to assess its safety, efficacy, and potential as a treatment for conditions that may benefit from growth hormone supplementation. These trials help to determine the optimal dosage, administration, and any potential side effects associated with the use of Tabimorelin as an oral growth hormone secretagogue.

Biological Activity

Potent, orally active ghrelin receptor (GHS-R1a) agonist (K i = 50 nM at human recombinant GHS-R1a). Stimulates GH release from rat pituitary cells with an EC 50 value of 2.7 nM. Induces hyperphagia and adiposity in lean rats, but not in leptin signaling-deficient ZDF rats.

InChI:InChI=1/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1

Upstream product

• 193085-20-0 ((3E)-1,1-Dimethyl-4-(N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)but-3-enyl)carbamic acid tert-butyl ester 
• 37553-65-4 N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 
• 129765-95-3 3-[(tert-butoxycarbonyl)amino]-3-methylbutanoic acid 
• 147577-61-5 (2R)-2-(N-(tert-butoxycarbonyl)-N-methylamino)-3-(2-naphthyl)-propionic acid 
• 181646-38-8 (1,1-dimethyl-3-oxo-propyl)-carbamic acid tert-butyl ester 
• 167216-22-0 tert-butyl (3-hydroxy-1,1-dimethyl-propyl)-carbamate 
• 193150-11-7 (R)-N-Methyl-2-methylamino-3-phenylpropionamide 
• 181646-42-4 (2E)-5-(tert-butyloxycarbonylamino)-5-methylhex-2-enoic acid 
• 181646-40-2 ethyl (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoate 
• 193085-18-6 N-Methyl-N-((R)-1-(methylcarbamoyl)-2-phenylethyl)carbamic acid tert-butyl ester 
• 186840-95-9 (2R)-N-Methyl-2-methylamino-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)-3-(2-naphthyl)propionamide 
• 193085-19-7 N-Methyl-N-{(1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl}carbamic acid tert-butyl ester 

Relevant articles and documents

Use of growth hormone or a growth hormone secretagogue for promoting bone formation

The invention provides a method of enhancing the healing of bone fractures in an animal subjected to distraction osteogenesis, the method comprising administering, to the animal in need thereof, a growth hormone or a growth hormone secretagogue in an amou